Etavopivat
Etavopivat is an investigational new drug that is being evaluated by FORMA Therapeutics for the treatment of sickle cell disease and thalassemia.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Etavopivat is an investigational new drug that is being evaluated by FORMA Therapeutics for the treatment of sickle cell disease and thalassemia. It is an allosteric activator of the erythrocyte pyruvate kinase R (PKR) enzyme.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1366116866 under CC BY-SA 4.0; modifications have been made.